Means Investment CO. Inc. grew its stake in Pfizer Inc. (NYSE:PFE) by 1.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,802 shares of the biopharmaceutical company’s stock after purchasing an additional 691 shares during the period. Means Investment CO. Inc.’s holdings in Pfizer were worth $1,442,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Kinloch Capital LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $25,000. Alpha DNA Investment Management LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. Penbrook Management LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $27,000. Orion Capital Management LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $29,000. Finally, Merrion Investment Management Co LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $30,000. Institutional investors own 67.36% of the company’s stock.
Several analysts have recently weighed in on PFE shares. TheStreet lowered shares of Pfizer from a “b” rating to a “c+” rating in a research report on Friday, March 5th. Mizuho cut their price target on shares of Pfizer from $44.00 to $42.00 and set a “buy” rating for the company in a report on Wednesday, February 3rd. SVB Leerink cut their price target on shares of Pfizer from $40.00 to $39.00 and set a “market perform” rating for the company in a report on Thursday, April 1st. Morgan Stanley dropped their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Friday, January 29th. Finally, JPMorgan Chase & Co. set a $36.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, February 3rd. Eleven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Pfizer has an average rating of “Hold” and an average target price of $38.47.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.46 by ($0.04). The firm had revenue of $11.68 billion for the quarter, compared to analyst estimates of $11.32 billion. Pfizer had a net margin of 17.85% and a return on equity of 24.88%. The firm’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.55 EPS. Equities research analysts predict that Pfizer Inc. will post 2.89 EPS for the current year.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Featured Story: The Role of a Fiduciary and Individual Investors
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.